COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #75 of 258
6/30 Late treatment study
Komissarov et al., medRxiv, doi:10.1101/2020.06.30.20143289 (Preprint)
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Source   PDF   Share   Tweet
Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HCQ group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalized control patient).

Komissarov et al., 6/30/2020, retrospective, Russia, Asia, Europe, preprint, 8 authors.
risk of viral load, 25.0% higher, RR 1.25, p = 0.45, treatment 26, control 10.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.